Baxter Shares Plunge as Q4 Loss Widens to $1.13 Billion

The $1.13 billion loss, equivalent to $2.19 per share, represents a significant expansion from the $512 million loss reported during the same period last year. A primary driver of the deficit was a $485 million goodwill impairment charge linked to the company’s Front Line Care unit. On an adjusted basis, earnings reached 36 cents per share, though management noted that performance was dampened by an unfavorable product mix and non-recurring inventory adjustments.

Operational Headwinds and Segment Growth

Total sales from continuing operations climbed 8% to $2.97 billion, reflecting steady demand across the portfolio. Growth was distributed across the company's core divisions:

• Medical products and therapies revenue rose 6%.
• Healthcare systems and technologies sales increased 5%.
• Pharmaceutical sales grew by 4%.

CEO Andrew Hider acknowledged the shortfall, stating that while the company maintained top-line momentum, the bottom line failed to meet internal benchmarks. Looking ahead, Baxter issued conservative guidance for 2026, forecasting sales growth to remain flat or rise by 1%. The company expects adjusted earnings for that year to fall between $1.85 and $2.05 per share.